Effect of Insulin Aspartate 30 Combined with Metformin Empagliflozin on Glycolipid Metabolism in Type 2 Diabetic Patients
Objective To analyze the effect of insulin aspartate 30 combined with metformin and empagliflozin on pa-tients with type 2 diabetes mellitus(T2DM).Methods A total of ninety-four T2DM patients admitted to Huai'an In-dustrial Park People's Hospital from September 2021 to September 2023 were conveniently selected as the study ob-jects,and were divided into two groups according to random number table method,with forty-seven cases in each group.The control group was treated with metformin and empagliflozin,and the observation group was treated with in-sulin aspartate 30.The clinical efficacy of the two groups was compared.Results The total effective rate of the observa-tion group was 93.62%,which was higher than 78.72%of the control group,and the difference was statistically signifi-cant(χ2=4.374,P=0.037).After treatment,the blood glucose index,blood lipid index and islet function index of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Insulin aspartate 30 combined with metformin empagliflozin can improve glucose and lipid me-tabolism and alleviate islet dysfunction in T2DM patients without serious adverse reactions.
Type 2 diabetesBlood glucoseBlood lipidAdverse reactionsGlycolipid metabolism
NETL
NSTL
万方数据
